| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17c6c7da627b7bead7208250127b52c2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2008-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7318c9578f98dfb243be33787465d8c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50f65a0d95d22a02f6ebc9b2b450a9f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c82ab7535642e77d9e182f64ddb3cbf5 |
| publicationDate |
2010-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20100037899-A |
| titleOfInvention |
Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody |
| abstract |
The present invention relates to an anticancer agent comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. Specifically, an anti-PD-1 antibody or an anti-PD-1 antibody that restores responsiveness of anergi-induced iNKT cells due to iNKT cell ligand administration An anticancer agent containing a PD-L1 antibody. The anti-PD-1 antibody or anti-PD-L1 antibody of the present invention can block the signal transduction of PD-1 or PD-L1 to prevent anergy induction of iNKT cells caused by iNKT cell ligand administration, and already anergi In the case of iNKT cells in the state, it restores the cytokine secretion ability to restore the reactivity of iNKT cells, and effectively reduce the number of pulmonary nodules in lung metastasis model using B16F10 melanoma cancer cells, effectively inducing the anti-cancer immune response of iNKT cells It can do and has excellent effect of inhibiting metastasis. Therefore, an anticancer agent comprising an anti-PD-1 antibody or an anti-PD-L1 antibody according to the present invention can be very useful for the treatment of cancer, especially metastatic cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20230092466-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170090523-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160128309-A |
| priorityDate |
2008-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |